Abstract
Among oral hypoglycemic agents (OHAs), imeglimin (Twymeeg) has been evaluated in clinical practice with Trials of Imeglimin for Efficacy and Safety (TIMES) 1-3 international studies. However, its gastrointestinal adverse effect (GIAE) would be an actual problem. Recently, imeglimin electrospinning nanofibers have been reported as a potential buccal antidiabetic therapeutic approach, which shows absorption not via the gastrointestinal (GI) tract. Imeglimin nanofibers have a diameter of 361 ± 54 nm and a drug-loading (DL) of 23.5 ± 0.2 μg/mg of fibers. The solid nanofibers disintegration takes only 2 ± 1 seconds. This novel medicine is expected to lead to optimal therapeutic outcomes with better patient compliance.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
